<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631147</url>
  </required_header>
  <id_info>
    <org_study_id>CSY-RFXM-PVT</org_study_id>
    <nct_id>NCT03631147</nct_id>
  </id_info>
  <brief_title>The Effect of Rifaximin on Portal Vein Thrombosis</brief_title>
  <acronym>ERPVT</acronym>
  <official_title>The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal
      vein thrombosis in cirrhotic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal vein thrombosis is not an uncommon complication in cirrhotic portal hypertension,
      which lead to a poor prognosis in endoscopic management of variceal bleeding. Evidence
      indicated that enoxaparin prevented PVT and liver decompensation via decreased rates of
      bacterial infections and lowered the potent inflammatory mediators such as interleukin-6.
      Rifaximin is a broad-spectrum antibiotic that exerts endotoxin-lowering and anti-inflammatory
      effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of portal vein thrombosis</measure>
    <time_frame>8 weeks</time_frame>
    <description>The changes of portal vein thrombosis in 8 weeks (include main portal vein, left and/or right portal vein, superior mesenteric vein, et al)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of portal vein thrombosis</measure>
    <time_frame>6 months</time_frame>
    <description>The changes of portal vein thrombosis in 8 weeks (include main portal vein, left and/or right portal vein, superior mesenteric vein, et al)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All clinical events</measure>
    <time_frame>8 weeks</time_frame>
    <description>All clinical events were defined as occurrence rebreeding, ascitic fluid infection, hepatorenal syndrome, hepatopulmonary syndrome, portal vein thrombosis, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All clinical events</measure>
    <time_frame>6 months</time_frame>
    <description>All clinical events were defined as occurrence rebreeding, ascitic fluid infection, hepatorenal syndrome, hepatopulmonary syndrome, portal vein thrombosis, or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rifaximin treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 400mg bid for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>400mg bid for 8 weeks</description>
    <arm_group_label>Rifaximin treatment group</arm_group_label>
    <other_name>XIFAXAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 y.o. ≤age≤75 y.o

          -  Cirrhotic patients had CTA confirmed portal vein trombosis

          -  D-dimer no more than five times the normal upper limit

        Exclusion Criteria:

          -  age &lt;18 y.o. or age &gt; 75 y.o.

          -  had portal cavernoma

          -  received anticoagulation treatment in the past 6 months

          -  splenectomy

          -  Known infection after endoscopic treatment (Fever, microbial cultures positive, et
             al.)

          -  Massive ascites or combined with other high risk factor that require prophylaxis use
             of antibiotics.

          -  Acute variceal bleeding within 5 days.

          -  Use of other antibiotics in the past 2 weeks

          -  Acute portal vein thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoquan HUANG, M.D.</last_name>
    <phone>008618801733835</phone>
    <email>huangxiaoquan1010@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyao CHEN, M.D.&amp; Ph.D</last_name>
    <email>chen.shiyao@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):435-46. doi: 10.1038/nrgastro.2014.36. Epub 2014 Apr 1. Review.</citation>
    <PMID>24686266</PMID>
  </reference>
  <reference>
    <citation>Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol. 2018 May-Jun;31(3):315-329. doi: 10.20524/aog.2018.0245. Epub 2018 Mar 3. Review.</citation>
    <PMID>29720857</PMID>
  </reference>
  <reference>
    <citation>Qi X, Bai M, Yang Z, Yuan S, Zhang C, Han G, Fan D. Occlusive portal vein thrombosis as a new marker of decompensated cirrhosis. Med Hypotheses. 2011 Apr;76(4):522-6. doi: 10.1016/j.mehy.2010.12.007. Epub 2011 Jan 8.</citation>
    <PMID>21216538</PMID>
  </reference>
  <reference>
    <citation>D'Amico G, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003 Sep;38(3):599-612.</citation>
    <PMID>12939586</PMID>
  </reference>
  <reference>
    <citation>Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Aguilar-Olivos NE, Alva-López LF, Fajardo-Ordoñez E, Ponciano-Rodríguez G, Northup PG, Intagliata N, Caldwell SH, Qi X, Méndez-Sánchez N. Thrombosis of the Portal Venous System in Cirrhotic vs. Non-Cirrhotic Patients. Ann Hepatol. 2018 May-June;17(3):476-481. doi: 10.5604/01.3001.0011.7392. Epub 2018 Apr 9.</citation>
    <PMID>29735798</PMID>
  </reference>
  <reference>
    <citation>Kimer N, Pedersen JS, Tavenier J, Christensen JE, Busk TM, Hobolth L, Krag A, Al-Soud WA, Mortensen MS, Sørensen SJ, Møller S, Bendtsen F; members of the CoRif study group. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. J Gastroenterol Hepatol. 2018 Jan;33(1):307-314. doi: 10.1111/jgh.13852.</citation>
    <PMID>28671712</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:11-26. doi: 10.1111/apt.13435. Review.</citation>
    <PMID>26618922</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 12, 2018</last_update_submitted>
  <last_update_submitted_qc>August 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

